Financing channel feed

Medicxi backs Chi­nese biotech's next-gen KRAS G12C drug with $40M in­jec­tion

Last year
China

For­eign in­vestors fled Chi­nese biotech af­ter the pan­dem­ic. They still haven’t come back

Last year
China

Con­tineum prices $110M IPO as IPF and neu­ro drugs ad­vance

Last year
Startups

Ex­clu­sive: Ex-Re­cur­sion team launch­es Leash Bio, chal­leng­ing AI field with its bet on need­ing more da­ta

Last year
AI

Ob­sid­i­an Ther­a­peu­tics rakes in $160M for sol­id tu­mor cell ther­a­py pro­gram

Last year
Cell/Gene Tx

Ex­clu­sive: Backed with $350M, se­cre­tive start­up Met­sera jumps in­to the obe­si­ty race

Last year
Startups

Apogee, Spyre founder launch­es its third biotech and heads straight to Nas­daq

Last year
Startups
Deals

Al­terome rais­es $132M to take next-gen can­cer drugs aimed at the 'un­drug­gable' in­to clin­ic

Last year
R&D

An­ti­body biotech Di­ag­o­nal Ther­a­peu­tics lands $128M to pur­sue rare dis­eases

Last year
Startups

Neu­roster­ix emerges with $63M to fol­low Karuna, Cerev­el

Last year
Startups

Con­tineum says it will seek $136M in IPO to back its mid-stage neu­ro drug

Last year
Startups

Bound­less starts IPO spring with $100M list­ing for can­cer small mol­e­cules

Last year
Startups

Up­dat­ed: Mod­er­na part­ners with Black­stone on flu shots, nab­bing up to $750M in R&D fund­ing

Last year
Deals
R&D

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo nabs $150M to in-li­cense more as­sets

Last year
Startups

Why Lenz picked a re­verse merg­er in­stead of an IPO: Q&A

Last year
People

Gal­der­ma tar­gets one of this year's biggest Eu­ro­pean IPOs with top-of-the-range share price

Last year
R&D

Bound­less Bio seeks $88M in IPO as it runs two Ph1 can­cer tri­als

Last year
Startups

For­mer Prometheus ex­ecs raise $400M for pre­ci­sion im­munol­o­gy start­up: 'The band is back to­geth­er'

Last year
Startups

Ex­clu­sive: ‘If you could hal­lu­ci­nate a pro­tein’: Proflu­ent snags $35M for gen­er­a­tive AI mod­els

Last year
Startups
AI

The megaround re­bound: Pri­vate biotechs rack up $100M+ fi­nanc­ings

Last year
Startups

Clasp Ther­a­peu­tics emerges with $150M based on work from Bert Vo­gel­stein, Drew Par­doll

Last year
Startups

'Cell ther­a­py with­out cell­s': Cap­stan rais­es $175M to test in vi­vo CAR-T

Last year
Startups
Cell/Gene Tx

Mid-stage neu­ro­science start­up En­grail rais­es $157M

Last year
Startups

Con­tineum Ther­a­peu­tics files for IPO with MS drug in PhII

Last year
Startups
First page Previous page 16171819202122 Next page Last page
A service from the Financial Times